Horizon Discovery Group plc to Present at 38th Annual J.P. Morgan Healthcare Conference
December 18 2019 - 7:00AM
Horizon Discovery Group plc to Present at
38th Annual J.P. Morgan Healthcare Conference
Cambridge, UK, 18 December
2019: Horizon Discovery Group plc (LSE: HZD)
("Horizon" or “the Group”), a global leader in the application of
gene editing and gene modulation technologies, today announces that
Terry Pizzie, Horizon's Chief Executive Officer, will provide an
overview and company update as well as host meetings with
investors, at the 38th Annual J.P. Morgan Healthcare Conference
which is being held in San Francisco, California between 13-16
January 2020.
Details of the presentation are as
follows:
|
Date: |
|
Wednesday, January 15, 2020 |
|
Time: |
|
08.00 - 08.25 am PST (16.00-16:25 pm GMT) |
A live webcast of the presentation will be
available and an archived replay accessible after the conference
for 90 days.
Investors interested in arranging a meeting with
the Company's management team during this conference should contact
the conference coordinator, or email
horizondiscovery@icrinc.com.
Ends
For further information from Horizon
Discovery Group plc, please contact:
Horizon Discovery Group
plcTerry Pizzie, Chief Executive OfficerJayesh Pankhania,
Chief Financial OfficerJon Davies, Head of Investor RelationsTel:
+44 (0) 1223 655 580
Numis Securities Limited (Broker and
NOMAD)Freddie Barnfield / Tom Ballard / Duncan
MonteithTel: +44 (0) 207 260 1000
Consilium Strategic Communications
(Financial Media and Investor Relations)Mary-Jane Elliott
/ Matthew Neal / Melissa GardinerTel: +44 (0) 20 3709
5700Email: horizon@consilium-comms.com
Zyme Communications (Trade and Regional
Media)Lorna CuddonTel: +44 (0)7787 502
947Email: lorna.cuddon@zymecommunications.com
Westwicke, an ICR Company (US Investor
Relations)Stephanie CarringtonTel. +1
646-277-1282Email: horizondiscovery@icrinc.com
About Horizon Discovery Group plc
www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD)
("Horizon") drives the application of gene editing and gene
modulation within the global life science market – supporting
scientists on the path from research to therapy.
Built upon more than a decade of experience in
the engineering of cell lines, Horizon offers an unmatched
portfolio of tools and services to help scientists gain a greater
understanding of gene function, identify genetic drivers behind
human disease, deliver biotherapeutics, cellular and gene therapies
for precision medicine as well as develop and validate diagnostic
workflows.
Horizon’s solutions enable almost any gene to be
altered, or its function modulated, in human and other mammalian
cell lines.
The Group’s customers include many of the
world’s foremost academic institutes, global pharmaceutical and
biotechnology companies as well as clinical diagnostic
laboratories. Insight into the challenges faced by these
organizations enables Horizon to focus efforts on development of
innovative solutions that not only differentiate the Group’s
offering, but also fuel development of the next wave of precision
medicines.
Horizon is headquartered in Cambridge, UK with
offices in USA and Japan. The Group is listed on the London
Stock Exchange's AIM market under the ticker HZD.
Horizons BetaPro COMEX S... (TSX:HZD)
Historical Stock Chart
From Jul 2024 to Aug 2024
Horizons BetaPro COMEX S... (TSX:HZD)
Historical Stock Chart
From Aug 2023 to Aug 2024
